This site looks better in landscape mode
Skip to content
Radically improving healthspan with a novel multifactorial approach to osteoarthritis
News
APPA shows promise in age related diseases
New data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggests that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on senescence – a process in which cells stop dividing as a natural consequence of ageing. Senescence plays a major role in the development of many age-related diseases, including osteoarthritis (OA).
The study, using a human chondrocyte (cartilage-forming) cell line, was carried out at the Institute of Biomedical Research of A Coruña (INIBIC) in Spain: OARSI 2023 Poster.
AKL have issued a Full Press Release.
